ESMO 2018 and more

In this episode, David Henry, MD, welcomes Daniel G. Haller, MD, to rehash research from ESMO 2018 as well as the way the meeting itself was run.

And Ilana Yurkiewicz, MD, stops by for this week’s Clinical Correlation. Dr. Yurkiewicz is a hematology fellow at Stanford and also is a columnist at MDedge Hematology/Oncology. More from Dr. Yurkiewicz here.

Subscribe to Blood & Cancer here:

Apple Podcasts
Google Podcasts

SHOW NOTES

By Emily Bryer, DO
Resident in the department of internal medicine, University of Pennsylvania Health System

• CheckMate 142: Durable clinical benefit with nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite high (MSI-H) and non-MSI-H colon cancer
  • Phase 2 study included 45 patients with metastatic colorectal cancer
  • Overall response rate (primary end point) was 60% and disease control rate was 84%
  • Almost every patient had some response and the therapy was well-tolerated
  • https://academic.oup.com/annonc/article/29/suppl_8/mdy424.019/5141601?searchresult=1

• Tribe 2: FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab
  • Phase 3 study of 654 patients with unresectable metastatic colorectal cancer
  • Progression free survival (primary end point) of FOLFOXIRI regimen was 18.9 months, compared with 16.2 months of the FOLFOX then FOLFIRI regimen
  • Side effects of FOLFOXIRI: febrile neutropenia, neutropenia, GI toxicities
  • https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122-9/fulltext

• Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomized, double-blind, placebo-controlled, phase 3 trial
  • Phase 3 study included 506 patients with metastatic gastric cancer
  • Trifluridine/tipiracil (oral drug) provided a 2-month overall survival advantage (primary end point), compared with placebo
  • Major side effect: neutropenia
  • https://www.ncbi.nlm.nih.gov/pubmed/30355453

• Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase 1b study in hepatocellular carcinoma (HCC)
  • Phase 1B study included 100 patients with HCC who had not received prior therapy
  • Disease control rate was high as was duration of response
  • Primary outcomes included safety and efficacy
  • The overall response rate was 34% and the most common side effect was hypertension
  • http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4074

In this episode, David Henry, MD, welcomes Daniel G. Haller, MD, to rehash research from ESMO 2018 as well as the way the meeting itself was run.

And Ilana Yurkiewicz, MD, stops by for this week’s Clinical Correlation. Dr. Yurkiewicz is a hematology fellow at Stanford and also is a columnist at MDedge Hematology/Oncology. More from Dr. Yurkiewicz here.

Subscribe to Blood & Cancer here:

Apple Podcasts
Google Podcasts

SHOW NOTES

By Emily Bryer, DO
Resident in the department of internal medicine, University of Pennsylvania Health System

• CheckMate 142: Durable clinical benefit with nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite high (MSI-H) and non-MSI-H colon cancer
  • Phase 2 study included 45 patients with metastatic colorectal cancer
  • Overall response rate (primary end point) was 60% and disease control rate was 84%
  • Almost every patient had some response and the therapy was well-tolerated
  • https://academic.oup.com/annonc/article/29/suppl_8/mdy424.019/5141601?searchresult=1

• Tribe 2: FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab
  • Phase 3 study of 654 patients with unresectable metastatic colorectal cancer
  • Progression free survival (primary end point) of FOLFOXIRI regimen was 18.9 months, compared with 16.2 months of the FOLFOX then FOLFIRI regimen
  • Side effects of FOLFOXIRI: febrile neutropenia, neutropenia, GI toxicities
  • https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122-9/fulltext

• Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomized, double-blind, placebo-controlled, phase 3 trial
  • Phase 3 study included 506 patients with metastatic gastric cancer
  • Trifluridine/tipiracil (oral drug) provided a 2-month overall survival advantage (primary end point), compared with placebo
  • Major side effect: neutropenia
  • https://www.ncbi.nlm.nih.gov/pubmed/30355453

• Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase 1b study in hepatocellular carcinoma (HCC)
  • Phase 1B study included 100 patients with HCC who had not received prior therapy
  • Disease control rate was high as was duration of response
  • Primary outcomes included safety and efficacy
  • The overall response rate was 34% and the most common side effect was hypertension
  • http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4074

In this episode, David Henry, MD, welcomes Daniel G. Haller, MD, to rehash research from ESMO 2018 as well as the way the meeting itself was run.

And Ilana Yurkiewicz, MD, stops by for this week’s Clinical Correlation. Dr. Yurkiewicz is a hematology fellow at Stanford and also is a columnist at MDedge Hematology/Oncology. More from Dr. Yurkiewicz here.

Subscribe to Blood & Cancer here:

Apple Podcasts
Google Podcasts

SHOW NOTES

By Emily Bryer, DO
Resident in the department of internal medicine, University of Pennsylvania Health System

• CheckMate 142: Durable clinical benefit with nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite high (MSI-H) and non-MSI-H colon cancer
  • Phase 2 study included 45 patients with metastatic colorectal cancer
  • Overall response rate (primary end point) was 60% and disease control rate was 84%
  • Almost every patient had some response and the therapy was well-tolerated
  • https://academic.oup.com/annonc/article/29/suppl_8/mdy424.019/5141601?searchresult=1

• Tribe 2: FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab
  • Phase 3 study of 654 patients with unresectable metastatic colorectal cancer
  • Progression free survival (primary end point) of FOLFOXIRI regimen was 18.9 months, compared with 16.2 months of the FOLFOX then FOLFIRI regimen
  • Side effects of FOLFOXIRI: febrile neutropenia, neutropenia, GI toxicities
  • https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122-9/fulltext

• Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomized, double-blind, placebo-controlled, phase 3 trial
  • Phase 3 study included 506 patients with metastatic gastric cancer
  • Trifluridine/tipiracil (oral drug) provided a 2-month overall survival advantage (primary end point), compared with placebo
  • Major side effect: neutropenia
  • https://www.ncbi.nlm.nih.gov/pubmed/30355453

• Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase 1b study in hepatocellular carcinoma (HCC)
  • Phase 1B study included 100 patients with HCC who had not received prior therapy
  • Disease control rate was high as was duration of response
  • Primary outcomes included safety and efficacy
  • The overall response rate was 34% and the most common side effect was hypertension
  • http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4074